Owkin, a NYC-based AI startup that uses machine learning to augment medical and biology research, closed an additional Series A funding.
The extension with GV raised the total to $18m to-date.
The company intends to use the funds to scale its artificial intelligence platform and develop new partnerships with research institutions and pharmaceutical companies.
Led by Thomas Clozel, M.D., CEO and co-founder, Owkin provides OWKIN Socrates, a proprietary platform designed to allow researchers in academia, hospitals, and the pharmaceutical industry to advance medical research. The platform uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes.
The company partners with pharmaceutical companies, including Amgen, Roche, and Ipsen, and develops scientific collaborations with medical institutions such as Institut Curie and Centre Léon Bérard. Owkin has recently announced a framework agreement with Inserm, one of the largest public research institutions solely focused on human health and medical research.